RESEARCH TRIANGLE PARK, N.C. and PALO ALTO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address chronic ...
The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing. Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ASGCT–OTXL joint venture platform goes live with demo at ASGCT 2026 Annual Meeting and applications opening this month for qualified Asset listings The platform is being demonstrated live during the ...
The American Society of Gene and Cell Therapy (ASGCT) is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates ...
– NociPro enables highly selective nociceptor targeting and potent NaV1.7 knockdown in rodents and non-human primates, supporting development candidate ETX301 for post‑amputation neuroma pain – – ...
Hans-Peter Kiem, MD, PhD, who holds the Stephanus Family Endowed Chair for Cell and Gene Therapy, has been awarded the 2026 George Stamatoyannopoulos Mentorship Award by the American Society of Gene ...
More than 10,000 known rare diseases affect over 30 million people in the United States. However, treatment options have been restricted due to small patient populations and limited commercial ...
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results